Executive Summary
Growing demand for advanced therapies requires scalable CDMO infrastructure. This capacity update outlines expanded global capabilities across cell and gene therapy manufacturing, viral vector production, fill/finish, and large molecule drug substance services. Watch to learn how enhanced GMP capacity supports clinical development and long-term commercial supply.
Key Takeaways
– Expanded cell and gene therapy manufacturing capacity
– Integrated viral vector and analytical capabilities
– Fill/finish and drug substance services
– Infrastructure supporting commercial readiness
About This Webinar
As advanced therapy pipelines grow, manufacturing capacity has become a critical constraint. Sponsors must secure CDMO partners with scalable GMP infrastructure capable of supporting clinical trials and commercial launch.
This webinar provides an update on Minaris Advanced Therapies’ expanded capacity across cell and gene therapy manufacturing. The session highlights viral vector production, analytical services, fill/finish operations, and large molecule drug substance capabilities.
Emphasis is placed on coordinated global facilities, structured technology transfer, and integrated quality systems that enable predictable growth from early development through commercialization. By aligning capacity expansion with operational excellence, sponsors gain greater timeline confidence and reduced transfer risk.
This session provides a concise overview of infrastructure investments designed to support long-term advanced therapy programs.
Who Should Watch This Webinar?
– Advanced therapy program leaders
– CMC and scale-up teams
– Sponsors planning commercial supply
Watch the full webinar to learn how our expanded CDMO capacity can support your cell and gene therapy program.
Watch nowAbout the speaker
Jordan Lovett
Head of Commercial Development
Jordan Lovett is the Head of Commercial Development at Minaris Advanced Therapies’ Philadelphia site. He oversees the company’s portfolio of client sponsored cell-based therapy programs —including CAR-T, MSC, and TIL products—as well as gene therapies such as AAV, Adenovirus, HSV, and Lentiviral platforms. With a primary focus on late-phase and commercial-stage assets, Jordan has more than a decade of experience in cell and gene therapy business development. He holds a Master’s degree in Biomedical Sciences from Rowan University (formerly UMDNJ) and a Bachelor of Science in Biology from Saint Joseph’s University.